The sigma 1 receptor (s 1 R) is a structurally unique transmembrane protein that functions as a molecular chaperone in the endoplasmic reticulum (ER), and has been implicated in cancer, neuropathic pain, and psychostimulant abuse. Despite physiological and pharmacological significance, mechanistic underpinnings of structure-function relationships of s 1 R are poorly understood, and molecular interactions of selective ligands with s 1 R have not been elucidated. The recent crystallographic determination of s 1 R as a homo-trimer provides the foundation for mechanistic elucidation at the molecular level. Here we report novel bioluminescence resonance energy transfer (BRET) assays that enable analyses of ligand-induced multimerization of s 1 R and its interaction with BiP. Haloperidol, PD144418, and 4-PPBP enhanced s 1 R homomer BRET signals in a dose dependent manner, suggesting their significant effects in stabilizing s 1 R multimerization, whereas (þ)-pentazocine and several other ligands do not. In non-denaturing gels, (þ)-pentazocine significantly decreased whereas haloperidol increased the fraction of s 1 R multimers, consistent with the results from the homomer BRET assay. Further, BRET assays examining heteromeric s 1 RBiP interaction revealed that (þ)-pentazocine and haloperidol induced opposite trends of signals.
Introduction
The sigma 1 receptor (s1R) is an intriguing transmembrane protein that does not share sequence homology to any known eukaryotic protein family, except for a fungal sterol isomerase (Hanner et al., 1996) . It has been characterized as a molecular chaperone in the endoplasmic reticulum (ER) (Hayashi and Su, 2007) , and may be a promising therapeutic target for several neuropsychiatric disorders (Kourrich et al., 2012; Maurice and Su, 2009 ). In addition, s 1 R has been shown to be involved in pain (Romero et al., 2016; Sanchez-Fernandez et al., 2017) , psychostimulant abuse Sabino et al., 2017) , and neurodegenerative diseases (Maurice and Goguadze, 2017; Nguyen et al., 2017) among others (Albayrak and Hashimoto, 2017; Soriani and Rapetti-Mauss, 2017; Wang et al., 2017) .
Depending on the physiological readout, s 1 R ligands have been described as "agonists" or "antagonists", as for G-protein coupled receptors (GPCRs). For instance, s 1 R "antagonists" demonstrate efficacy in counteracting neuropathic pain (Romero et al., 2016) and drug seeking behavior in stimulant abuse , whereas s 1 R "agonists" display favorable effects in depression (Fishback et al., 2010) . However, it is worth noting that the efficacy distinction between "agonist" and "antagonist" has not reached consensus in a therapeutic context. For instance, in the development of antipsychotics both an "antagonist" (Ferris et al., 1986; Gilmore et al., 2004) and an "agonist" (Albayrak and Hashimoto, 2017) have been found to be beneficial. Furthermore, the underlying molecular mechanistic differences between agonists and antagonists have not been well characterized across different pathological contexts (Katz et al., 2016; Merlos et al., 2017) , and it must be noted that some of the observations and interpretations are not monolithic . For example, the s 1 R ligand BMY 14802 was characterized as both an antagonist and an agonist (Schoenwald et al., 1995; Taylor et al., 1993) . This discrepancy can be attributed to readouts and interpretations at different downstream effector levels. Indeed only a few studies have evaluated the efficacy of s 1 R ligands specifically at the level of s 1 R-s 1 R interaction (Gomez-Soler et al., 2014; Gromek et al., 2014; Mishra et al., 2015) .
s 1 R has a multitude of client proteins and the interactions with them may influence the nature of ligand action and signaling outcome . Thus, client protein coupling and subsequent effector activation or inactivation have been reported as the major biological function of s 1 R . Among the different client proteins, in particular, binding immunoglobulin protein (BiP), also known as heat shock 70 kDa protein 5, has been well-characterized (Ha et al., 2014; Miki et al., 2015; Ono et al., 2013; Penas et al., 2011) and shown to regulate ER-originated events such as calcium release and receptor trafficking (Hayashi and Su, 2007) .
To understand the molecular mechanism of ligands on s 1 R, simplified signaling-independent methods are expected to better categorize the ligands, which may require going beyond the canonical agonist/antagonist definitions. In light of recent studies on s 1 R homomerization in response to a variety of ligands (Gromek et al., 2014; Mishra et al., 2015) , ligand-induced changes on receptor multimerization state may provide at least qualitative criterion for functional categorization. Recent crystal structures of ligand-bound s 1 R, which are solved in homo-trimers, have revealed its transmembrane topology as well as the ligand binding site (Schmidt et al., 2016) . Even though discrepancies with previous reports with regard to the structural topology (OrtegaRoldan et al., 2015; Ossa et al., 2017) remain, the high-resolution structural information revealed by the crystal structures sets the path to fundamental understanding of biophysical and pharmacological properties of s 1 R at the molecular level. Specifically, the identification of the homomerization interface provides a framework to design the constructs that are feasible to study the ligandinduced changes of multimerization state with pharmacological assays.
The bioluminescence resonance energy transfer (BRET) assay is a reliable protein-protein proximity assay. The methodology is capable of uncovering both distance changes between two proteins (Pfleger et al., 2006) , and large conformational rearrangements within a protein such as ligand-induced conformational changes of GPCRs (Lohse et al., 2012) . Importantly, BRET is suited for real-time kinetic tracking of the movements of labeled proteins. Here we develop novel BRET assays to characterize the ligand-induced changes in the homomerization of s 1 R and its interaction with BiP. The findings in s 1 R homomer BRET assay were validated by a biochemical assay, and were further shown to correlate with the results from computational modeling. Herein, we report the pharmacological characterizations of 8 known s 1 R ligands in a signaling-independent manner.
Materials and methods

s 1 R radioligand binding in guinea pig cortex
Male Hartley guinea pig cortices were dissected from freshly harvested brains (shipped cold in phosphate-buffered saline (PBS) buffer from BioReclamation IVT) and frozen at À80 C for future use. On test day, thawed guinea pig cortices were suspended and homogenized in 20 vol (w/v) (10 mM Tris.HCl, 0.32 M Sucrose, pH 7.4 at 25 C) with a glass-teflon apparatus and centrifuged (~1200 rpm) for 10 min at 4 C. The supernatant was collected in a clean tube and the pellet re-suspended in 10 ml of cold buffer and centrifuged again (~1200 rpm) for 10 min at 4 C. The supernatants were pooled together and centrifuged (20,000 rpm) for 15 min at 4 C. The final pellet was suspended in ice-cold binding buffer at 50 mg/ml concentration (original wet weight). A Bradford protein assay (Bio-Rad, Hercules, CA) was used to determine the protein concentration present in the tissue preparation (1.25 mg/ml). All test compounds were freshly dissolved in 30% DMSO and 70% H 2 O to a stock concentration of 1 mM or 100 mM. To assist the solubilization of free-base compounds, 10 ml of glacial acetic acid was added along with the DMSO (in place of 10 ml final H 2 O volume).
Each test compound was then diluted into 10 half-log serial dilutions using 30% DMSO as the vehicle. Radioligand competition experiments were conducted in 96-well plates containing 300 ml fresh binding buffer, 50 ml of diluted test compound, 100 ml of tissue preparation (125 mg/well total protein amount), and 50 ml of radi- HEK293T cells were grown as described below in section 2.4. Upon reaching 80e90% confluence, non-transfected HEK293T cells were harvested using pre-mixed Earle's Balanced Salt Solution (EBSS) with 5 mM EDTA (Life Technologies) and centrifuged at 3000 rpm for 10 min at 21 C. The supernatant was removed and the pellet was resuspended in 10 ml hypotonic lysis buffer (5 mM MgCl 2 , 5 mM Tris, pH 7.4 at 4 C) and centrifuged at 20,000 rpm for 30 min at 4 C. The pellet was then resuspended in fresh EBSS binding buffer made from 8.7 g/l Earle's Balanced Salts without phenol red (US Biological, Salem, MA) and 2.2 g/L sodium bicarbonate, pH to 7.4. A Bradford protein assay (Bio-Rad, Hercules, CA) was used to determine the protein concentration. On test day, the experiments were conducted in 96-well plates containing 300 ml fresh binding buffer, 50 mL of diluted test compound, 100 mL of membranes (100 mg/well total protein), and 50 mL of radioligand diluted in binding buffer ([ 3 Membranes from non-transfected HEK293T were collected as described above. HEK293T cells, either intact or transfected with s 1 R-Venus and s 1 R-NanoLuciferase, were harvested using premixed Earle's Balanced Salt Solution (EBSS) with 5 mM EDTA (Life Technologies) and centrifuged at 1200 rpm for 5 min at 21 C to prevent cell lysis. The supernatant was removed and the pellet was then resuspended in fresh EBSS binding buffer made from 8.7 g/L Earle's Balanced Salts without phenol red (US Biological, Salem, MA) and 2.2 g/L sodium bicarbonate, pH to 7.4. A Bradford protein assay (Bio-Rad, Hercules, CA) was used to determine the protein concentration. The experiments were conducted in 96-well plates containing 300 ml fresh binding buffer, 50 ml of 30% DMSO vehicle (3% DMSO final concentration for total binding) or 10 mM (þ)-pentazocine (final concentration for non-specific binding), 100 ml of membranes or whole cell preparation (100 mg/well total protein), and 50 ml of radioligand diluted in binding buffer ([ 3 H]-(þ)-pentazocine: 3 nM final concentration). The reactions were incubated at room temperature and terminated by filtration through Perkin Elmer Uni-Filter-96 GF/B (presoaked in 0.5% polyethylenimine) at different time points. Non-specific binding was subtracted from the total binding at each time point and the obtained specific binding values were normalized to the maximum specific binding achieved at 120 min. T 1/2 values represent the time necessary to obtain 50% of the radioligand bound. B max values (membranes: 871 fmol/mg; whole non-transfected cells: 1041 fmol/mg and BRET-transfected cells: 4289 fmol/mg) were calculated as well from the association kinetic experiments. All the values were determined from at least 3 independent experiments performed in triplicate and are reported as mean ± SEM. ]-(þ)-pentazocine: 3 nM final concentration). The reactions were incubated at room temperature and terminated by filtration through Perkin Elmer UniFilter-96 GF/B (presoaked in 0.5% polyethylenimine) at different time points. For each time point the amount of specific binding was normalized to 100% (total specific binding in presence of the vehicle) and 0% (residual radioligand bound in presence of 500 nM (þ)-pentazocine). The data represent the average of two independent experiments with triplicate determinations for each drug concentration at the different time points. The multiple statistical comparison was obtained by two-way ANOVA followed by posthoc Tukey analysis.
DNA constructs, transfection, and cell culture
Human s 1 R is fused in pcDNA3.1 plasmid to the NanoLuciferase fragments, full length NanoLuciferase (NL), or mVenus (VN; monomeric YFP variant) N-terminally or C-terminally by introduction of restriction enzyme site to generate the following constructs. The N-terminal fragment (NL1) or C-terminal fragment (NL2) of NanoLuciferase is subcloned as follows: KpnI-NL1-BamHI-
Full length NanoLuciferase or mVenus is subcloned as follows: KpnI-NL-BspEI-s 1 R, NheI-VN-HindIII-s 1 R, s 1 R-XhoI-VNXbaI, s 1 R-XhoI-NL-XbaI. N-terminal fusion of FLAG-2xHis 8 to s 1 R is made as previously described . Human BiP is fused in pcDNA3.1 plasmid to venus as follows: NheI-VN-HindIIIBiP, BiP-XhoI-VN-XbaI. All the constructs were confirmed by sequence analysis.
For luciferase complementation, a constant amount of total plasmid (2 mg) was transfected in human embryonic kidney cells 293T (HEK 293T) using polyethylenimine (PEI; Sigma-Aldrich, St. Louis, MO) in a 1 to 2 ratio in 6-well plates. For acceptor saturating BRET, using PEI, a constant amount of total plasmid cDNA (5 mg) in varied donor:acceptor ratios was transfected in HEK 293T in 6-well plates. For drug induced BRET, a constant amount of total plasmid cDNA (15 mg) in 1:24 (¼ donor:acceptor ratio) was transfected using PEI. Cells were maintained in culture with Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and kept in an incubator at 37 C and 5% CO 2 . Experiments were performed approximately 48 h post-transfection.
Luciferase complementation and bioluminescence resonance energy transfer (BRET)
Luciferase complementation is conducted as follows. Cells were harvested, washed, and resuspended in PBS. Approximately 200,000 cells/well were distributed in 96-well plates. Luminescence was measured at 485 nm using a Mithras LB940 reader (Berthold Technologies, Bad Wildbad, Germany).
Acceptor saturating BRET is performed as described previously (Sohy et al., 2009) . Briefly, after cell resuspension and distribution in 96-well plates as described in luciferase complementation, expression of venus fusion proteins was estimated by measuring fluorescence at 535 nm following excitation at 485 nm. Expression of NL fusion proteins was estimated by measuring the luminescence of the cells after incubation with 5 mM coelenterazine h. In parallel, BRET was measured as a ratio between measurements at 535 nm (fluorescence) and at 485 nm (luminescence) using a Mithras LB940 reader (Berthold Technologies, Bad Wildbad, Germany). Results are plotted as fluorescence over luminescence vs. basal-subtracted BRET ratio.
Drug induced BRET is conducted as reported previously (Urizar et al., 2011) . Cells were prepared in 96-well plates as in acceptor saturating BRET. 5 mM coelenterazine h (substrate for BRET) was added to each well. Three minutes after addition of coelenterazine h, ligands [(þ)-pentazocine (Sigma), PRE-084 (Tocris), NE100 (Tocris), JHW007 (Newman lab), cocaine (NIDA), PD144418 (Tocris), haloperidol (Tocris), 4PPBP (Tocris)] in series of dilution were added to each well. BRET was measured as in acceptor saturating BRET. Results are calculated for the BRET change (BRET ratio for the corresponding drug minus BRET ratio in the absence of the drug). E max values are expressed as the basal subtracted BRET change in the dose-response graphs.
Non-denaturing gel assay
As previously described , HEK293 cells were stably transfected with N-terminal FLAG-2xHis 8 tagged s 1 R (FHs 1 R). Confluent cells in 24-well plates were first incubated with haloperidol or vehicle at 37 C for 0.5 h in culture medium, followed by addition of (þ)-pentazocine (if indicated) and incubation at 37 C for 1 h. Cells were then washed with cold PBS with 1 mM MgCl 2 and 0.1 mM CaCl 2 (PBSCM), harvested and lysed with lysis buffer (0.1% glyco-diosgenin, NaCl 150 mM, EDTA 1 mM, Tris 50 mM, pH 7.5, and protease inhibitors) for 2 h at 4 C. Supernatants after centrifugation (20,000 g, 10 min) were mixed with 2x sample buffer (8% perfluorooctanoic acid (PFO), 40% glycerol, bromophenol blue 0.005%, Tris 100 mM, pH 7.5) to a final concentration of 4% PFO, and heated at 37 C for 10 min. Samples were run in 5e15% polyacrylamide Tris-glycine gels (running buffer: 0.1% PFO, 25 mM Tris, 192 mM glycine, pH 8.3). Proteins were transferred to PVDF membranes and immunoblotted with rat monoclonal anti-Flag L5 antibody (Biolegend, San Diego, CA).
Data analysis
All experiments were repeated at least three times. Regression and other statistical analyses were performed using GraphPad Prism version 7.0 (GraphPad Software, San Diego, CA).
Molecular docking and simulations
The crystal structure of s 1 R in complex with PD144418 (s 1 R/ PD144418, PDB ID 5HK1 (Schmidt et al., 2016) ) was used as the starting point for our modeling studies. Except for PD144418, all other compounds described in this study were docked into the binding site revealed by the crystal structure using the induced-fit docking (IFD) protocol (Sherman et al., 2006) implemented in the Schrodinger suite (release 2016-4) . Since all of these compounds, except for PRE-084, possess a nitrogen that should be protonated at pH 7, they are expected to form a salt bridge with Glu172 in the binding site. The pK a of the nitrogen on PRE-084 was calculated to be 5.82 ± 1.47 at pH 7 (which is consistent with the experimentally measured value of 6.2, see text), using the Epik protocol in the Schrodinger suite (release 2016-4). However, PRE-084 was still prepared as the protonated form since the protonation is likely to happen in the micro-environment of the binding site (see Supplementary Method and Supplementary Results). Therefore, the formation of the salt bridge was used as a filter for the docking poses. We considered all stereoisomers for each ligand, including those for the phenylcyclohexane ring of PRE-084, and those resulting from two possible ways in protonating the aforementioned nitrogen for haloperidol, 4-PPBP, cocaine, (þ)-pentazocine, and JHW007. Several poses for each ligand or stereoisomer with significantly different orientations in the binding site were further evaluated by binding pose metadynamics simulations (Clark et al., 2016) in which the ligand RMSD deviation from the starting pose was set to be the collective variable. Poses that are clearly unfavored in the metadynamics simulations, i.e., with higher RMSD fluctuations and lower hydrogen bond persistency, were discarded, while others were selected for the molecular dynamics (MD) simulations. In the end, one to three poses were selected for each compound for the following MD simulations (Table S1 ).
MD simulations of the s 1 R/ligand complexes were performed in an explicit water and 1-palmitoyl-2-oleoylphosphatidylcholine (POPC) lipid bilayer environment using Desmond MD System (version 4.9; D. E. Shaw Research, New York, NY) with the OPLS3 force field for protein, ligand, and lipids (Harder et al., 2016) and with the SPC water model. The missing residues at the N-terminus of s 1 R in the crystal structure of s 1 R/PD144418 were constructed using MODELLER (John and Sali, 2003) . Each of the s 1 R/ligand complexes were then placed into the POPC lipid bilayer using the orientation of s 1 R/PD144418 retrieved from the Orientation of Proteins in Membranes database (Lomize et al., 2006) . The system charges were neutralized, and 150 mM NaCl was added. Simulations were performed with a cutoff distance of 12 Å for the nonbonded interactions; and the particle mesh Ewald method was used to evaluate long-range electrostatic effects. In the isothermalisobaric (NPT) ensemble, constant temperature (310 K) and 1 atm constant pressure were maintained with Langevin dynamics on an anisotropic flexible periodic cell, with a constant-ratio constraint applied on the lipid bilayer in the X-Y plane. Each system was first minimized and then equilibrated with restraints on the ligand heavy atoms and protein backbone atoms, followed by production runs with all atoms unrestrained, as described previously (Michino et al., 2015 (Michino et al., , 2017 . For each complex, we collected multiple trajectories (Table S1 ).
Ligand pose analysis
The stability of each ligand in the MD simulations were evaluated by calculating i) the RMSD of the ligands using the ligand pose in the last frame of each trajectory as the reference, and ii) the distance of the hydrogen on the charged N to the carboxyl group of Glu172. For the following analysis, we chose the most stable pose of each ligand that had the ligand RMSD below 1.5 Å for at least 300 ns with the persistent formation of the salt bridge e whereas most of the compounds had only one pose that was clearly better than the others, the two isomers of (þ)-pentazocine were similarly stable in the MD simulations and both were included in the subsequent studies.
To classify the s 1 R ligands based on their binding modes, we calculated the interaction frequencies of these ligands with the binding site residues. For the reasons described in the Discussion (section 4), we did not include cocaine in this analysis. Two poses of (þ)-pentazocine were combined so the following analysis was not biased. A protein residue was considered to form an interaction with the ligand if any heavy atom-heavy atom distance between them was within 4 Å. To obtain the mean interaction frequency, we randomly sampled 100 frames from each of the MD trajectories of the stable poses of each complex, which was repeated for 30 times and the mean contact frequency values were plotted as the heat map. Then, a hierarchical clustering was performed to classify the s 1 R ligands based on the identities of contacting residues and their interaction frequencies with the ligands. To prevent the big difference caused by some individual residues, e.g., those with high contact frequency, we used Canberra distance to calculate the
, in which p i , q i represent the contact frequency between the ligand p or q and the residue i; while n represents the total number of interaction residues being considered; if "agonist" (Maurice and Su, 2009; Rousseaux and Greene, 2015) ) in the membrane preparation of HEK 293T cells, and found they were comparable to those determined in guinea pig cortex (Table 1 , K d values were determined by homologous competitive binding as described in the Methods section), which has been routinely used in pharmacological studies of s 1 R ligands (Su, 1982; Tam and Cook, 1984) . Note the K d value of (þ)-pentazocine for guinea pig cortex was similar to that reported previously (Bowen et al., 1993 A few different topological orientations of N-and C-termini relative to the membrane have been proposed for s 1 R, based on the hydrophobicity analysis and truncation mutation studies (Brune et al., 2013; Kourrich et al., 2012) . Such topological insight of s 1 R is key to understanding its homomeric interaction as well as its interactions with client proteins. Thus, guided by the recent homotrimeric crystal structures, we studied the relative topology between N-and C-termini by both bimolecular complementation and BRET approaches (Fig. 2) . By fusing recently reported NanoLuciferase split fragments (i.e. NL1 and NL2) (Yano et al., 2018) to proteins, the level of complementation between NL1 and NL2 is assessed by luminescence ( Fig. 2A) , from which we can deduce the protein-protein proximity. As a positive control, we used dopamine D 2 receptor (D 2 R) C-terminal fusions of NL1 and NL2 (D 2 R-NL1:D 2 R-NL2), a pair of constructs that are known to readily complement ( Fig. 2A) . As a negative control, we used D 2 R-NL1 and a non-membrane associated cytosolic protein FRB fused to NL2 (D 2 R-NL1:FRB-NL2), because they approach to each other only randomly ( Fig. 2A) . For s 1 R, NL1 and NL2 are fused not only to the same ends, i.e., either both to the N-terminus, NL1-s 1 R:NL2-s 1 R (NL1-s 1 :NL2-s 1 ), or both to the C-terminus, s 1 R-NL1:s 1 R-NL2 (s 1 -NL1:s 1 -NL2), but also to the opposite ends, i.e., NL1-s 1 :s 1 -NL2 or NL2-s 1 :s 1 -NL1 Compound HEK 293T membrane Guinea pig cortex
1091 ± 79 (3) ( Fig. 2A) . Consistent with the topology revealed by the crystal structures that N-and C-termini are on two sides of the membrane, only the same-end fusion s 1 R pairs and the D 2 R-NL1:D 2 R-NL2 pair showed a significantly higher luminescence level above the D 2 R-NL1:FRB-NL2 pair (Fig. 2C) . We then used an acceptor saturating BRET method, a commonly-used ratiometric assay that has the advantage of withstanding off-target ligand interaction with a luciferase. As previously reported (Marullo and Bouvier, 2007) , a saturating profile and higher net BRET values are the signature of specific interactions between the donor and acceptor (i.e., NL and VN), whereas linear or low net BRET values indicate a random collision between the donor and acceptor and thus not likely to form a complex between the two fused-proteins. Consistent with the findings from the above bimolecular NanoLuciferase complementation, only the same-end fusion construct pairs, the N-terminal pair NL-s 1 R:VN-s 1 R (NLs 1 :VN-s 1 ) and the C-terminal pair s 1 -NL:s 1 -VN, satisfied the high and saturable BRET signals, whereas the opposite-end fusion construct pairs (NL-s 1 :s 1 -VN and s 1 -NL:VN-s 1 ) exhibited a low linear BRET profile (Fig. 2B,D) .
3.3. PRE-084 shows unique kinetics in entering the ligand binding site of s 1 R Photoaffinity labeling experiments (Fontanilla et al., 2008) and the recently solved s 1 R crystal structures (Schmidt et al., 2016) demonstrate that s 1 R ligand binding site is on the same side of the membrane as its C-terminus. However, the locale of the binding site with regard to the membrane topology is much less certain. The Cterminus (and therefore the binding site) has been variously asserted to be located within the ER lumen (Hayashi and Su, 2007) , in the cytoplasm (Aydar et al., 2002) , or outside the cell (Balasuriya et al., 2013 Figure 2A and B) . Normalized to total binding in the absence of cold ligand and complete displacement by 500 nM cold (þ)-pentazocine as 100% and 0%, respectively, haloperidol, JHW007, and NE100 showed immediate displacement even at 15 min of incubation for both membrane preparation and whole cells (note the negative values indicate that the tested cold ligand may reach the binding sites faster than (þ)-pentazocine). However, PRE-084 showed significantly slower kinetics than the others in the whole cell assay, whereby it only displaced 60. Figure 2C) . We found all the tested ligands, including PRE-084, displaced [ 3 H]-(þ)-pentazocine in these cells as fast as in the membrane preparation of the non-transfected cells, indicating that the transiently transfected plasma membrane is permeable to s 1 R ligands, possibly due to compromised membrane integrity (Grandinetti et al., 2012) . From the binding kinetics, we calculated B max and K d for intact whole cells (1041 ± 540 fmol/mg and 1.7 ± 0.1 nM, respectively), BRET-transfected whole cells (4289 ± 2745 fmol/mg and 2.0 ± 0.3 nM), and membrane preparation (871 ± 403 fmol/mg and 3.3 ± 1.4 nM). As expected, BRET-transfected whole cells showed Figure 2D) .
Taken together, while other tested ligands exhibited cell permeability comparable to [ 3 H]-(þ)-pentazocine in intact cells, PRE-084 showed slower kinetics. The lack of slower kinetics of PRE-084 in the membrane preparation and the BRET-transfected cells suggests that the process of permeation through the intact membrane may play a role in its kinetics. However, whereas the In all four time points tested, there were clear dose-response effects by haloperidol, 4-PPBP, and PD144418, but weaker or almost no effects by (þ)-pentazocine, PRE-084, NE-100, JHW007, and cocaine (Fig. 3AeD) . The results at later time points (10, 30, and 60 min) showed more prominent increases in the induced BRET signals for haloperidol, 4PPBP, and PD144418, but very little by the others (Fig. 3AeD ). The differences in potencies among haloperidol, 4PPBP, and PD144418 correlated with their different binding affinities (Table 2) , although the potencies are consistently lower than the K i values. We categorized haloperidol, 4PPBP, and PD144418 to be active, whereas the other compounds were inactive in this assay. Even though there could be a spectrum of E max values depending on the s 1 R ligands, we set the threshold by two-way ANOVA Dunnett test at the level of PD144418 E max (~0.02) resulting in the classification of ligands into two groups: haloperidol, 4PPBP, and PD144418 that showed positive dosedependent induction of BRET signaling, and (þ)-pentazocine, PRE-084, NE100, JHW007, and cocaine that produced no detectable effects on BRET signaling. To demonstrate that the lack of BRET signals in the single-ligand mode was not due to the inability of (þ)-pentazocine, PRE-084, NE-100, JHW007, or cocaine to bind to s 1 R, we used a competition mode of the assay by adding 1 mM haloperidol (Fig. 3EeH ) or 1 mM PD144418 (Fig. 3IeL) prior to addition of the tested ligands (see Methods). We found all five compounds showed dose-dependent effects in the competition mode e the negative values in Fig. 3EeL indicate direct competition, as the BRET signals induced by the pre-added haloperidol or PD144418 were subtracted to 0 in the analysis. The inhibition potencies for these drugs were correlated with their relative differences in binding affinities as well, though the overall potency values were more right-shifted (less potent) than the K i values. Further, when the lower efficacy (E max shown in the single-ligand mode) ligand PD144418 was displaced by haloperidol or 4PPBP, both of which have higher E max values, positive BRET signals were induced as compared to the negative signal observed for the non-efficacious ligands (Fig. 3IeL) .
Of note, when we carried out the same assays using the N-terminal NL-s 1 :VN-s 1 construct pair (Supplementary Figure 3) , the data could not be deciphered by conventional regression analysis. Thus, even though the BRET ratios for the N-terminal pair were higher than the C-termini pair, it was more feasible to study the structure-activity relationships (SAR) of these s 1 R ligands in the s 1 R homomerization with the C-terminal fusion constructs.
3.5. Haloperidol promotes the formation of higher order s 1 R homomers in a non-denaturing gel assay Because haloperidol increased s 1 R homomeric interaction in our BRET assays, we further explored ligand effects on s 1 R multimerization using a biochemical method described recently . In non-denaturing gels, we observed low molecular weight (MW) bands likely corresponding to monomer and dimer of s 1 R, and high MW bands indicative of s 1 R multimers. Concentrations of 0.1 or 1 mM haloperidol dramatically increased the multimer band intensities and decreased the low MW band intensities, in a dose dependent manner. Consistent with enhanced BRET signals by haloperidol in Fig. 2 , this result showed that haloperidol promoted or stabilized s 1 R multimerization. On the other hand, 10 mM (þ)-pentazocine decreased the density of multimer bands while increasing those of low MW bands (Fig. 4) . In addition, we evaluated the capability of (þ)-pentazocine to inhibit the multimer-promoting effect by haloperidol, using two ratios of haloperidol and (þ)-pentazocine, 0.1:10 mM (1:100) and 1:10 mM (1:10). Results showed that (þ)-pentazocine inhibited haloperidol's effect in a dose dependent manner (Fig. 4) .
These results suggest that the well-characterized s 1 R agonist (þ)-pentazocine and antagonist haloperidol had distinct effects on the multimerization state of s 1 R. Whereas haloperidol promotes the formation of higher order homomers, (þ)-pentazocine shifts the equilibrium in the opposite direction.
Computational study reveals a structural basis for ligand categorization
The crystal structures of s 1 R/PD144418 and s 1 R/4-IBP (PDB ID 5HK1 and 5HK2) (Schmidt et al., 2016) reveal an occluded and elongated binding cavity in a cupin-like b-barrel, with the highly conserved Glu172 located near the center of the cavity, forming a salt bridge with the ligands.
Because the crystal structures have revealed an unexpected topology for the number of transmembrane segments and the locations of the N-and C-termini, we first evaluated the stability of these structures in the lipid bilayer environment. Thus, we immersed the trimers of s 1 R/PD144418 complex and the apo state of s 1 R (starting from the structure with PDB ID 5HK1) in the explicit lipid-bilayer (see section 2.8) and carried out prolonged MD simulations (Table S1 ). We found the integrities of the s 1 R structure Fig. 4 . Non-denaturing gel analysis of drug-induced s 1 R-s 1 R interaction. Cells expressing FH-s 1 R (MW: 32 kDa) were incubated with haloperidol in culture medium at 37 C for 0.5 h, followed by incubation of (þ)-pentazocine for 1 h. Cells were lysed with GDN lysis buffer and subjected to PFO-PAGE. Flag antibodies detected high-MW multimeric and low-MW (likely monomer and dimer) bands, based on their apparent MW. Quantified results of multimeric band signals (mean ± SEM, n ¼ 4 experiments), with a representative blot. *P < .05, **P < .01, one way ANOVA and post-hoc Dunnett's test, compared with vehicle. Faint signals (~50 kDa) are likely due to partial degradation of dimeric s 1 R. and the trimer interface were well retained in both conditions. Thus, whereas the functional dynamics of the homomer states of s 1 R remains to be fully characterized, these studies support the crystal structures as providing a reliable framework to investigate the SAR of structurally diverse s 1 R ligands.
We then systematically characterized the binding modes of all the s 1 R ligands in Fig. 1 . We carried out molecular docking of these compounds in all their possible stereoisomeric forms and selected several potential binding poses to be further evaluated by both metadynamics and prolonged conventional MD simulations (see section 2.7). From the simulation results, we identified the most stable modes for each ligand (see section 2.8, and Supplementary Figure 5 ). Whereas we could narrow down the most stable pose for the other ligands to one, we found two isoforms of (þ)-pentazocine that are protonated differently on the charged N atom were similarly stable, and thus we have included the results of both forms in our following interacting-residue analysis.
Based on the MD simulation results, we carried out a hierarchical clustering analysis of s 1 R ligands according to their interacting patterns with the binding site residues (see section 2.9). When the number of clusters is reduced to two, we found that haloperidol, PD144418 and 4-PPBP form one cluster, while the rest compounds are in the other cluster, the results of which are correlated well with those from the homomer BRET assay. Interestingly, a fluorophenyl ring of JHW007 protruded into a small pocket that was not occupied by any of haloperidol, PD144418 and 4-PPBP (Fig. 5C ) and formed a polar interaction with Thr189 (Fig. 5D) . Similarly, PRE-084 and one of the (þ)-pentazocine isomers could also occupy this pocket, with the latter stably forming a hydrogen bond (H-bond) with Thr189 (Fig. 5D ). This pocket is encircled by Val84, Asn85, Ala86, Leu186, Asp188, Thr189, Thr198, and Thr202, and a water molecule is found in this pocket in the crystal structure of s 1 R/PD144418. Among these residues, Asn85
and Asp188 face the central tunnel formed by the trimer, while Thr198 forms a H-bond with Asp195, which interacts with His116 and Arg119 of another monomer. Thus, this small pocket appears to be associated with multimerization, and the different interactions with this pocket between the two groups of ligands are potentially correlated with their divergent propensities in promoting or stabilizing the formation of s 1 R multimer. Figure 4A and B). BiP-VN C-terminal fusion does not seem to be a good sensor for BRET since the C-terminal domain plays a role in substrate binding for BiP . To be consistent with the s 1 R homomer BRET, we used the s 1 -NL:VN-BiP pair to evaluate the impact of s 1 R ligand binding on this coupling. Interestingly, (þ)-pentazocine showed the bimodal dose response effect at 2.5 and 10 min time points, whereas haloperidol showed a negative induced BRET signal at 60 min (Fig. 6 ). In the competition mode of the assay, the presence of 1 mM (þ)-pentazocine diminished the negative BRET signal induced by haloperidol. These results suggest two temporally distinct events: one immediately after the ligand addition and one at a later time point. A similar trend was observed in the N-terminal fusion pair (NL-s 1 R:VN-BiP; see Supplementary Results and Supplementary Figure 4C ).
Discussion
In (þ)-pentazocine binding e in a recent study, the s 2 R was found to have a K d of 54.1 nM for haloperidol, which is similar to that of s 1 R and cannot be resolved in slope analysis; in comparison, s 2 R has a K d of 2.47 mM for (þ)-pentazocine, which is a much higher value than the K d at s 1 R (Alon et al., 2017) . Employing a novel s 1 R homomer BRET assay that detects ligand-induced changes between s 1 R monomers, we are able to identify ligands that produced a positive dose-dependent increase of s 1 R-s 1 R homomer BRET signals, such as haloperidol, 4-PPBP, and PD144418. Although (þ)-pentazocine and other ligands did not produce clear response in this assay, it is possible that a higher sensitivity is necessary to discern subtle BRET signals in transiently transfected cells with abundantly expressed BRET sensor proteins. However, they attenuated the increase in BRET signals elicited by haloperidol, PD144418 or 4-PPBP. The fact that the displacement of PD144418 by haloperidol or 4-PPBP resulted in a higher E max value is consistent with graded effects among the haloperidol-like ligands (Fig. 3K,L) .
Because s 1 R homomer BRET assays did not directly measure functional outcomes after s 1 R ligand binding, we do not use "agonist" and "antagonist" in the interpretation of our results.
While traditionally s 1 R agonists and antagonists are defined by various functional assays such as anti-nociception, the molecular mechanisms that delineate s 1 R agonists and antagonists remain to be elucidated. Indeed, in label-free dynamic mass redistribution assays, we did not see significant changes by all tested s 1 R ligands, indicating that their s 1 R-dependent signaling events are very different from GPCR-dependent ones (Schroder et al., 2010) and perhaps not as robust near the plasma membrane (Supplementary Results and Supplementary Figure 6 ). Although some ligands exhibited unexpected results in the BRET assays, we did observe similar phenotypes in "agonists" ((þ)-pentazocine and PRE-084) and "antagonists" (haloperidol and PD144418), consistent with their characterization in the literature (Maurice and Su, 2009 ). Nonetheless, the unexpected phenotypes of NE-100, and 4-PPBP are intriguing. It is plausible that such discrepancies could be attributed to subtle responses by these ligands that are not detected by our BRET assays, or masked by their off-target effects, or likely due to extrinsic factors such as client proteins. In addition, the inactivity of cocaine in our s 1 R homomer BRET assay is worth noting. Although the low potency of cocaine in the single-ligand homomer BRET assays renders it difficult to interpret its phenotype, based on the results at 30 and 60 min time points (Fig. 3C and  D) , it is tempting to speculate that cocaine is more like haloperidol in this aspect. Interestingly, JHW007 has been found to counter-act the stimulant and reinforcing effects of cocaine , and is different from haloperidol in our BRET assays.
Indeed, JHW007 is a dual acting ligand that binds to both s 1 R and the dopamine transporter (DAT) with high affinities (Agoston et al., 1997; Hiranita et al., 2017; Katz et al., 2004) . JHW007 stabilizes DAT in a more inward-facing conformation from that stabilized by cocaine (Abramyan et al., 2017; Beuming et al., 2008; Bisgaard et al., 2011; Loland et al., 2008) . Thus, if cocaine and JHW007 belong to different categories of s 1 R ligands, we can envision that JHW007 antagonizes the actions of cocaine at both DAT and s 1 R, two important targets that have been found to interact dynamically at or near the plasma membrane Sambo et al., 2017) . Interestingly, to the extent of our simulations in this study, we could identify a stable pose of cocaine that does not protrude into the small pocket occupied only by JHW007, (þ)-pentazocine, and PRE-084.
Homomer BRET does not provide information directly on how many monomers constitute the s 1 R complex as the BRET ratio is not quantitative for a donor:acceptor stoichiometric ratio. However, it is worth noting that the E max are saturable (e.g., haloperidol, PD144418, and 4PPBP) indicating that the equilibrated donor:-acceptor ratio is capped at a certain level within the BRETparticipating populations. Although we may not know the stoichiometric ratio, it is interesting to observe graded saturation levels of E max among different s 1 R ligands, which may indicate different higher order homomers. To evaluate the ligand effects on the homomerization state of s 1 R directly, we employed a biochemical assay described recently . By comparing the results from these nondenaturing gels and BRET assays, we conclude that the increase of the BRET signal is associated with the formation of higher-order homomers, based on the following two common trends: first, the observation that haloperidol promotes the multimerization and (þ)-pentazocine competes against that effect in gel assays is in line with the differences observed between these two ligands in the homomer BRET assay; second, the multimer band is made of different populations and distinctly heavier than a trimer, indicating the possibility of several high-order multimers, which may be reflected by different strengths of BRET signals elicited by the haloperidol-like ligands; third, the density changes for the multimer are inversely correlated with those of low-MW populations (monomer and dimer), consistent with the observed displacement of haloperidol by (þ)-pentazocine in the competition BRET assay.
s 1 R has been shown to regulate chaperone activities of BiP in the ER via s 1 R-BiP interaction (Hayashi and Su, 2007; OrtegaRoldan et al., 2013) . The opposite effects of (þ)-pentazocine and haloperidol demonstrated by our s 1 R-BiP BRET assay, along with their effects in the homomer BRET assay, argue that the s 1 R-BiP interaction is modulated differently by these s 1 R ligands. Indeed, they also induced distinct effects on s 1 R homomerization in biochemical assays using non-denaturing gels. Interestingly, the opposite pharmacological profiles between the homomer BRET and s 1 R-BiP BRET can be interpreted as that the promotion of homomerization by haloperidol diminishes s 1 R-BiP interaction, whereas unchanged or diminished homomerization by (þ)-pentazocine may facilitate s 1 R interacting with BiP. We propose that the physiological significance of s 1 R homomerization is tightly linked to the interaction with its client protein BiP. Such a scenario closely resembles the hypothesis proposed on the interaction between s 1 R and DAT in a recent study . Determining whether similar changes occur during the interaction of s 1 R with other client proteins will require further investigations. Although there may be different interpretations of ligand effects on the s 1 R-BiP interaction, both current and previous studies (Hayashi and Su, 2007) suggest that s 1 R ligands dynamically regulate s 1 R-BiP interactions. In BRET assays, we were able to examine time-course and dose-response of s 1 R ligand in live cells, which was not achieved by previous co-immunoprecipitation methods. Thus, the bimodal dose response and time dependent change of the (þ)-pentazocine effect (Fig. 6 ) may indicate that the ligand-induced cellular trafficking of s 1 R affects its interaction with ER-resident BiP. Indeed, a (þ)-pentazocine-induced decrease in s 1 R-BiP interaction at later time points in our study here coincides with a previous report of 30 min (þ)-pentazocine incubation time point .
Note, however, since BRET appears to happen across the membrane in our HEK 293T cell model, our BRET results on s 1 R-BiP interaction are consistent with, but do not definitively prove the orientation of s 1 R relative to the ER lumen and cytoplasm depicted in the cartoons in Fig. 6 and Supplementary Figure 4, i.e., with the N terminus facing the ER lumen (or the extracellular side). Interestingly, recent work by the Yang group (Mavylutov et al., 2017) suggests that the C terminus of s 1 R may face the ER lumen.
In our MD simulations, we found that the trimer models of the s 1 R/PD144418 complex and its apo form embedded in lipid bilayers are highly stable in terms of the integrity of the ligand binding site and the trimer interface. This finding supports that the crystal structure from which these models were derived is in a valid conformation, thereby the N-and C-termini of the protein are on two different sides of the membrane. The results of our topological analysis of s 1 R by the BRET assay resonate with this conclusion as well. Based on these consistent conclusions from different approaches, we carried out a s 1 R structure-based SAR study to investigate the structural basis for the different BRET profiles of the two groups of s 1 R ligands. In particular, we found JHW007, (þ)-pentazocine, and PRE-084 protrude into a small pocket near the trimer interface that was not occupied by haloperidol, 4PPBP, and PD144418. Thus, our computational results described herein reveal the initial clues of the SAR profile for the tested ligands. Whereas our work establishes a novel molecular biophysical approach to classify s 1 R ligands, it is important to point out that the resulting classifications of the ligands are not necessarily in contradiction to previous characterizations of these ligands, many of which are based on functional readouts downstream of the initial s 1 R-ligand interactions. Such readouts are assumed to have integrated their impact from the interactions between s 1 R and its client proteins, and the off-target effects of ligands. Thus, our BRET approach sheds light on the ligand-induced conformational changes of s 1 R, in combination and correlation with the s 1 R structure-based SAR studies, it would provide a framework at the atomistic level to investigate the structure-function relationship of s 1 R.
Conclusions
We established a novel s 1 R homomer BRET assay to profile the pharmacological properties of s 1 R ligands based on induced changes in s 1 R homomerization, and identified multimerpromoting and non-promoting ligands, the conclusion of which is substantiated by a biochemical assay at the protein-protein interaction level. The results of a complementary BRET assay on the s 1 RBiP interaction reflected the reciprocal pharmacological behavior seen in s 1 R homomerization. In characterizing the binding modes of the experimentally tested compounds at s 1 R with extensive MD simulations, we revealed initial clues for the structural basis that may be responsible for stabilization of the homomer.
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